MCID: TRN018
MIFTS: 57

Transitional Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Transitional Cell Carcinoma

MalaCards integrated aliases for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 12 75 53 15 17
Carcinoma, Transitional Cell 44 72
Transitional Cell Neoplasm 12 72
Transitional Cell Carcinoma of Bladder 72
Carcinoma Transitional Cell 55
Urothelial Cell Carcinoma 12
Transitional Cell Tumor 12
Transitional Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2671
MeSH 44 D002295
NCIt 50 C2930 C6783
SNOMED-CT 68 27090000
UMLS 72 C0007138 C0279680 C0334265

Summaries for Transitional Cell Carcinoma

Disease Ontology : 12 A carcinoma that derives from transitional epithelial cells.

MalaCards based summary : Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to bladder papillary transitional cell neoplasm and renal pelvis transitional cell carcinoma. An important gene associated with Transitional Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Lapatinib and Panitumumab have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and lymph node, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 75 Transitional cell carcinoma, is a type of cancer that typically occurs in the urinary system. It is the... more...

Related Diseases for Transitional Cell Carcinoma

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 625, show less)
# Related Disease Score Top Affiliating Genes
1 bladder papillary transitional cell neoplasm 34.7 TP53 KRT20 FGFR3
2 renal pelvis transitional cell carcinoma 34.7 UPK3A KRT7
3 papillary transitional carcinoma 34.1 KRT7 KRT20
4 small cell carcinoma of the bladder 33.2 KRT7 KRT20
5 urinary tract papillary transitional cell benign neoplasm 33.1 TP53 KRT20 FGFR3
6 bladder urothelial carcinoma 32.8 UPK3A TP53 KRT7 KRT20 HRAS FGFR3
7 in situ carcinoma 31.9 TP53 ERBB2 EGFR CDKN2A CDH1
8 prostate cancer 31.6 TP53 PTGS2 PTEN KRT18 HRAS ERBB3
9 cystitis 31.2 UPK3A UPK1A PTGS2 KRT20
10 serous cystadenocarcinoma 31.2 TP53 HRAS ERBB2
11 inverted papilloma 31.2 TP53 KRT7 KRT20 CDKN2A
12 exanthem 31.1 HRAS ERBB2 EGFR
13 papillary carcinoma 31.0 KRT7 KRT20 ERBB2 CDH1
14 non-invasive bladder papillary urothelial neoplasm 31.0 UPK3A TP53 FGFR3
15 bladder carcinoma in situ 31.0 UPK2 TP53 KRT7 CDKN2A
16 bladder squamous cell carcinoma 31.0 UPK2 TP53 CDKN2A
17 papilloma 30.9 TP53 PTEN KRT7 KRT20 FGFR3 CDKN2A
18 appendix adenocarcinoma 30.9 KRT7 KRT20
19 cervix carcinoma 30.9 TP53 FGFR3 CDKN2A
20 renal cell carcinoma, nonpapillary 30.9 KRT7 KRT20 IFNA2 EGFR CDH1
21 horseshoe kidney 30.8 KRT7 KRT20 EGFR
22 mammary paget's disease 30.8 KRT7 KRT20 ERBB2 EGFR
23 myeloma, multiple 30.8 TP53 HRAS FGFR3 CDKN2A
24 suppression of tumorigenicity 12 30.7 UPK3A TP53 PTEN HRAS CDH1
25 mucinous adenocarcinoma 30.7 KRT7 KRT20 EGFR CDKN2A
26 carcinosarcoma 30.7 TP53 PTEN KRT7 HRAS ERBB2
27 signet ring cell adenocarcinoma 30.6 KRT7 KRT20 CDH1
28 ovarian brenner tumor 30.6 UPK3A KRT7 KRT20 KRT18
29 glandular cystitis 30.6 UPK3A KRT7 KRT20
30 paget disease, extramammary 30.6 KRT7 KRT20 ERBB2
31 cystadenocarcinoma 30.6 TP53 KRT7 HRAS ERBB2
32 cystitis cystica 30.5 UPK2 KRT7 KRT20
33 papillary adenocarcinoma 30.5 TP53 KRT7 ERBB2 CDH1
34 small cell carcinoma 30.5 TP53 PTEN KRT7 KRT20 EGFR CDKN2A
35 actinic keratosis 30.5 TP53 PTGS2 KRT20 CDKN2A
36 merkel cell carcinoma 30.5 TP53 KRT7 KRT20
37 chronic cystitis 30.5 UPK3A KRT7 KRT20
38 bladder cancer 30.5 UPK3A UPK2 TP53 KRT20 KRT18 HRAS
39 linitis plastica 30.4 KRT7 KRT20 CDH1
40 vesicoureteral reflux 1 30.3 UPK3A UPK1B UPK1A
41 ovarian cancer 30.3 TP53 PTEN KRT7 ERBB3 ERBB2 EGFR
42 renal pelvis carcinoma 30.2 UPK3A KRT7 KRT20
43 glioma 30.1 TP53 PTEN ERBB2 EGFR CDKN2A
44 adenocarcinoma 30.1 TP53 PTGS2 PTEN HRAS FGFR3 ERBB3
45 clear cell renal cell carcinoma 30.1 TP53 PTEN KRT7 CDH1
46 intrahepatic cholangiocarcinoma 30.1 TP53 KRT7 KRT20 EGFR CDH1
47 squamous cell carcinoma 30.1 TP53 PTGS2 PTEN HRAS FGFR3 ERBB2
48 lung squamous cell carcinoma 30.0 TP53 PTEN HRAS FGFR3 EGFR CDH1
49 renal cell carcinoma, papillary, 1 29.9 TP53 PTEN KRT7 HRAS FGFR3 ERBB2
50 endometrial cancer 29.9 TP53 PTEN KRT7 HRAS ERBB2 EGFR
51 vulva cancer 29.9 UPK3A TP53 KRT7 EGFR CDKN2A
52 pancreatic cancer 29.8 TP53 HRAS ERBB2 EGFR CDKN2A CDH1
53 cervical adenocarcinoma 29.7 TP53 PTGS2 KRT7 KRT20 ERBB2 CDKN2A
54 adenoid cystic carcinoma 29.5 TP53 PTEN KRT7 KRT20 HRAS ERBB2
55 small cell cancer of the lung 29.5 TP53 PTEN KRT7 KRT20 KRT18 EGFR
56 cervical cancer 29.5 TP53 PTGS2 PTEN HRAS FGFR3 ERBB2
57 colorectal adenocarcinoma 29.3 TP53 PTGS2 KRT7 KRT20 HRAS EGFR
58 bladder disease 29.3 UPK3A UPK2 UPK1A TP53 KRT20 FGFR3
59 hepatocellular carcinoma 29.2 TP53 PTGS2 PTEN KRT7 HRAS EGFR
60 gastric adenocarcinoma 28.6 TP53 PTGS2 PTEN KRT7 KRT20 HRAS
61 cholangiocarcinoma 28.5 TP53 PTGS2 PTEN KRT7 KRT20 KRT18
62 colorectal cancer 27.7 TP53 PTGS2 PTEN KRT7 KRT20 KRT18
63 lung cancer 27.6 TP53 PTGS2 PTEN KRT7 KRT20 KRT18
64 sarcomatoid transitional cell carcinoma 12.8
65 ureter transitional cell carcinoma 12.6
66 ovary transitional cell carcinoma 12.6
67 infiltrating renal pelvis transitional cell carcinoma 12.6
68 prostate transitional cell carcinoma 12.6
69 endometrial transitional cell carcinoma 12.6
70 transitional cell carcinoma of the corpus uteri 12.6
71 invasive bladder transitional cell carcinoma 12.5
72 fallopian tube transitional cell carcinoma 12.5
73 non-papillary transitional cell carcinoma of the bladder 12.5
74 bartholin's gland transitional cell carcinoma 12.4
75 urethra transitional cell carcinoma 12.4
76 kidney pelvis sarcomatoid transitional cell carcinoma 12.4
77 urinary tract non-invasive transitional cell neoplasm 12.4
78 infiltrating ureter transitional cell carcinoma 12.3
79 urethral cancer 11.6
80 fallopian tube carcinoma 11.6
81 costello syndrome 11.6
82 prostate cancer, hereditary, 1 11.3
83 prostate cancer, hereditary, 12 11.3
84 prostate cancer, hereditary, 13 11.3
85 prostate cancer, hereditary, 11 11.3
86 prostate cancer, hereditary, 2 11.3
87 breast papillomatosis 10.8 ERBB2 CDKN2A
88 gastric papillary adenocarcinoma 10.8 TP53 ERBB2
89 breast intraductal proliferative lesion 10.8 ERBB2 EGFR
90 spitz nevus 10.8 TP53 HRAS CDKN2A
91 brain ependymoma 10.8 TP53 EGFR
92 male reproductive system disease 10.8 TP53 PTEN CDH1
93 meningeal melanomatosis 10.8 TP53 HRAS CDKN2A
94 fallopian tube endometrioid adenocarcinoma 10.8 ERBB2 CDKN2A
95 breast cystic hypersecretory carcinoma 10.8 ERBB2 CDH1
96 bartholin's gland disease 10.7 TP53 ERBB3 CDKN2A
97 skin squamous cell carcinoma 10.7 TP53 HRAS CDKN2A
98 breast squamous cell carcinoma 10.7 TP53 ERBB2 EGFR
99 tongue disease 10.7 TP53 CDKN2A CDH1
100 cerebral convexity meningioma 10.7 TP53 CDH1
101 acneiform dermatitis 10.7 HRAS ERBB2 EGFR
102 ovarian serous cystadenocarcinoma 10.7 TP53 HRAS ERBB2
103 gliomatosis cerebri 10.7 TP53 PTEN EGFR
104 primary peritoneal carcinoma 10.7 TP53 ERBB2 EGFR
105 conjunctival intraepithelial neoplasm 10.7 IFNA2 CDKN2A
106 esophagus adenocarcinoma 10.7 TP53 PTGS2 ERBB2
107 sporadic breast cancer 10.7 TP53 PTEN ERBB2
108 nasopharyngeal disease 10.7 TP53 CDKN2A CDH1
109 cervix disease 10.7 TP53 CDKN2A CDH1
110 inflammatory breast carcinoma 10.7 ERBB2 EGFR CDH1
111 luminal breast carcinoma 10.7 ERBB3 ERBB2 EGFR
112 cervical squamous cell carcinoma 10.7 TP53 CDKN2A CDH1
113 breast carcinoma in situ 10.7 TP53 ERBB2 EGFR
114 intestinal benign neoplasm 10.6 TP53 PTGS2 HRAS
115 lipid-rich carcinoma 10.6 ERBB2 EGFR CDH1
116 inverted transitional papilloma 10.6 KRT7 CDKN2A
117 estrogen-receptor positive breast cancer 10.6 TP53 ERBB2 EGFR
118 prostate squamous cell carcinoma 10.6 TP53 KRT7 HRAS
119 recurrent respiratory papillomatosis 10.6 TP53 PTGS2 EGFR
120 testicular germ cell tumor 10.6 TP53 PTEN HRAS FGFR3
121 malignant peritoneal mesothelioma 10.6 EGFR CDKN2A
122 tongue cancer 10.6 TP53 CDKN2A CDH1
123 breast scirrhous carcinoma 10.6 ERBB2 EGFR
124 epithelial-myoepithelial carcinoma 10.6 TP53 KRT7 HRAS
125 neutropenia 10.6
126 tubular adenocarcinoma 10.6 KRT20 ERBB2 CDH1
127 female reproductive endometrioid cancer 10.6 TP53 PTEN KRT7
128 male reproductive organ cancer 10.6 TP53 PTEN CDH1
129 adenosquamous carcinoma 10.6 TP53 KRT7 EGFR
130 colorectal adenoma 10.6 TP53 PTGS2 HRAS
131 adenosquamous lung carcinoma 10.6 HRAS FGFR3 ERBB2 EGFR
132 granulosa cell tumor of the ovary 10.6 TP53 KRT7 ERBB2
133 malignant spiradenoma 10.6 TP53 KRT7
134 necrotizing sialometaplasia 10.6 TP53 KRT7 CDKN2A
135 protoplasmic astrocytoma 10.6 TP53 PTGS2
136 differentiated thyroid carcinoma 10.6 TP53 HRAS EGFR
137 vulvar intraepithelial neoplasia 10.6 TP53 KRT7
138 penile disease 10.6 TP53 IFNA2 CDKN2A
139 hydronephrosis 10.6
140 giant cell glioblastoma 10.6 TP53 PTEN FGFR3 EGFR
141 cystic basal cell carcinoma 10.6 KRT7 KRT20
142 sarcomatoid renal cell carcinoma 10.6 TP53 IFNA2 CDH1
143 benign breast adenomyoepithelioma 10.6 KRT7 EGFR
144 pharynx cancer 10.6 TP53 EGFR CDKN2A CDH1
145 progesterone-receptor negative breast cancer 10.6 ERBB2 EGFR
146 mucinous lung adenocarcinoma 10.6 HRAS ERBB3 ERBB2 EGFR
147 pleomorphic carcinoma 10.6 TP53 KRT7 EGFR
148 appendix disease 10.6 KRT7 KRT20 HRAS
149 papillary serous adenocarcinoma 10.6 TP53 KRT7 KRT20
150 cerebrum cancer 10.6 TP53 PTEN EGFR CDKN2A
151 supratentorial cancer 10.6 TP53 PTEN EGFR CDKN2A
152 bladder adenocarcinoma 10.6 KRT7 KRT20 HRAS
153 gliosarcoma 10.6 TP53 PTEN FGFR3 EGFR
154 barrett's adenocarcinoma 10.6 TP53 PTGS2 ERBB2 CDKN2A
155 grade iii astrocytoma 10.6 TP53 PTEN EGFR CDKN2A
156 central nervous system cancer 10.6 TP53 PTEN EGFR CDKN2A
157 nervous system cancer 10.6 TP53 PTEN EGFR CDKN2A
158 laryngeal disease 10.6 TP53 EGFR CDKN2A CDH1
159 ovarian clear cell carcinoma 10.6 TP53 PTEN KRT7
160 meningioma, familial 10.6 TP53 PTEN CDKN2A CDH1
161 malignant syringoma 10.5 KRT7 KRT20
162 bile duct adenoma 10.5 KRT7 KRT20 CDKN2A
163 eccrine sweat gland neoplasm 10.5 TP53 KRT7 KRT20
164 respiratory system disease 10.5 TP53 HRAS EGFR CDH1
165 li-fraumeni syndrome 10.5 TP53 PTEN EGFR CDKN2A
166 malignant peripheral nerve sheath tumor 10.5 TP53 EGFR CDKN2A
167 appendix cancer 10.5 TP53 KRT7 KRT20
168 transverse colon cancer 10.5 KRT7 KRT20
169 breast ductal carcinoma 10.5 TP53 ERBB2 EGFR CDH1
170 laryngeal squamous cell carcinoma 10.5 TP53 EGFR CDKN2A CDH1
171 cystic teratoma 10.5 TP53 KRT7 KRT20
172 mixed cell type cancer 10.5 TP53 KRT7 HRAS ERBB2
173 pancreatic mucinous cystadenoma 10.5 KRT7 KRT20 HRAS
174 nasal cavity adenocarcinoma 10.5 TP53 KRT7 HRAS CDKN2A
175 seminal vesicle adenocarcinoma 10.5 KRT7 KRT20
176 mucinous bronchioloalveolar adenocarcinoma 10.5 KRT7 KRT20 CDKN2A
177 breast adenocarcinoma 10.5 TP53 PTEN ERBB2 EGFR
178 ovary adenocarcinoma 10.5 TP53 KRT7 HRAS ERBB2
179 oligodendroglioma 10.5 TP53 PTEN EGFR CDKN2A
180 large intestine adenocarcinoma 10.5 KRT7 KRT20 CDH1
181 pseudomyxoma peritonei 10.5 TP53 KRT7 KRT20
182 adenoid squamous cell carcinoma 10.5 KRT7 KRT20 CDH1
183 cecum adenocarcinoma 10.5 KRT7 KRT20 HRAS
184 colloid adenoma 10.5 TP53 KRT20
185 cell type benign neoplasm 10.5 TP53 KRT7 HRAS CDKN2A
186 adenocarcinoma in situ 10.5 KRT7 KRT20 CDKN2A
187 infiltrative basal cell carcinoma 10.5 KRT7 KRT20 CDH1
188 squamous cell papilloma 10.5
189 bile duct adenocarcinoma 10.5 TP53 KRT7 HRAS CDH1
190 small intestine cancer 10.5 KRT7 KRT20 HRAS
191 gastrointestinal stromal tumor 10.5 TP53 PTEN EGFR CDKN2A
192 krukenberg carcinoma 10.5 KRT7 KRT20
193 proliferating trichilemmal cyst 10.5 KRT7 KRT18
194 ovarian cancer 1 10.5 TP53 KRT7 ERBB2 CDH1
195 biliary papillomatosis 10.5 TP53 KRT7 KRT20 HRAS
196 uterine anomalies 10.5 TP53 PTEN ERBB2 CDKN2A CDH1
197 lung benign neoplasm 10.5 TP53 KRT7 HRAS EGFR
198 hidradenocarcinoma 10.5 TP53 KRT7 ERBB2 EGFR
199 ampulla of vater cancer 10.5 TP53 KRT7 KRT20 HRAS
200 basaloid squamous cell carcinoma 10.4 TP53 KRT7 EGFR CDKN2A
201 glycogen-rich clear cell breast carcinoma 10.4 TP53 KRT7 KRT20 CDKN2A
202 eyelid carcinoma 10.4 KRT7 KRT20
203 large cell neuroendocrine carcinoma 10.4 KRT7 KRT20 EGFR
204 endocervical adenocarcinoma 10.4 TP53 KRT7 KRT20 CDKN2A
205 tongue squamous cell carcinoma 10.4 TP53 CDKN2A CDH1
206 pancreatic ductal carcinoma 10.4 TP53 KRT7 KRT20 CDKN2A
207 gastrointestinal system benign neoplasm 10.4 TP53 PTGS2 KRT7 HRAS
208 pre-malignant neoplasm 10.4 TP53 ERBB2 EGFR CDKN2A CDH1
209 mucoepidermoid carcinoma 10.4 KRT7 ERBB2 EGFR
210 microglandular adenosis 10.4 TP53 KRT18 ERBB2 EGFR
211 penile cancer 10.4 TP53 IFNA2 EGFR CDKN2A
212 cholecystitis 10.4 TP53 KRT18 CDKN2A CDH1
213 vulvar disease 10.4 UPK3A TP53 KRT7 CDKN2A
214 oral cavity cancer 10.4 TP53 PTEN ERBB2 EGFR CDH1
215 bile duct cancer 10.4 TP53 KRT7 EGFR
216 glioblastoma multiforme 10.4 TP53 PTEN ERBB2 EGFR CDKN2A
217 gastric diffuse adenocarcinoma 10.4 UPK2 KRT7 KRT20 CDH1
218 rare tumor 10.4
219 ureteral benign neoplasm 10.4
220 esophageal disease 10.4 TP53 PTGS2 ERBB2 EGFR CDKN2A
221 ovary epithelial cancer 10.4 TP53 KRT7 HRAS ERBB2 CDH1
222 malignant ovarian surface epithelial-stromal neoplasm 10.4 TP53 KRT7 HRAS ERBB2 CDH1
223 alopecia 10.4
224 ovarian cystic teratoma 10.3 KRT7 KRT20 IFNA2
225 nasopharyngeal carcinoma 10.3 TP53 HRAS EGFR CDKN2A CDH1
226 tonsil cancer 10.3 TP53 KRT7 ERBB2 CDKN2A CDH1
227 colonic disease 10.3 TP53 PTGS2 HRAS EGFR CDH1
228 cervical adenosquamous carcinoma 10.3 PTGS2 KRT7 EGFR CDKN2A
229 intestinal disease 10.3 TP53 PTGS2 HRAS EGFR CDH1
230 ductal carcinoma in situ 10.3 TP53 PTGS2 ERBB2 EGFR CDH1
231 stomach disease 10.3 TP53 PTGS2 ERBB2 EGFR CDH1
232 bronchiolo-alveolar adenocarcinoma 10.3 KRT7 KRT20 EGFR CDH1
233 oncocytic breast carcinoma 10.3 KRT7 EGFR
234 oral cancer 10.3 TP53 PTGS2 EGFR CDKN2A CDH1
235 prostatic hypertrophy 10.3
236 melanoma, cutaneous malignant 1 10.3 TP53 PTEN IFNA2 HRAS CDKN2A
237 bartholin's gland benign neoplasm 10.3 ERBB3 CDKN2A
238 oropharynx cancer 10.3 TP53 KRT7 EGFR CDKN2A CDH1
239 medulloblastoma 10.3 TP53 PTEN ERBB3 ERBB2 EGFR
240 lung acinar adenocarcinoma 10.3 KRT7 KRT20
241 mucositis 10.3
242 thrombocytopenia 10.3
243 ureteral obstruction 10.3
244 female reproductive system disease 10.3 TP53 PTEN ERBB2 EGFR CDKN2A CDH1
245 dermatomyositis 10.2
246 acute cystitis 10.2
247 prostatic adenoma 10.2
248 end stage renal failure 10.2
249 renal pelvis adenocarcinoma 10.2 KRT7 CDH1
250 chordoma 10.2 PTEN KRT7 EGFR CDKN2A CDH1
251 prostatic hyperplasia, benign 10.2
252 pyelonephritis 10.2
253 47,xyy 10.2
254 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
255 kidney disease 10.2
256 chromosomal triplication 10.2
257 lymphoepithelioma-like carcinoma 10.2 KRT7 KRT20 KRT18 CDH1
258 vulval paget's disease 10.2 UPK3A KRT7 KRT20 ERBB2 CDKN2A
259 constipation 10.2
260 choriocarcinoma 10.2
261 urinary tract obstruction 10.2
262 adenoma 10.2
263 nephrogenic adenoma 10.2
264 vulva adenocarcinoma 10.2 UPK3A KRT7 KRT20 ERBB2 CDKN2A
265 gallbladder cancer 10.2 TP53 PTGS2 ERBB2 EGFR CDKN2A CDH1
266 bladder diverticulum 10.1
267 retinoblastoma 10.1
268 pyuria 10.1
269 leiomyosarcoma 10.1
270 familial retinoblastoma 10.1
271 endometrial adenocarcinoma 10.1 TP53 PTEN KRT7 ERBB2 EGFR CDKN2A
272 respiratory system cancer 10.1 TP53 PTEN HRAS ERBB2 EGFR CDKN2A
273 breast cancer 10.1
274 schistosoma mansoni infection, susceptibility/ 10.1
275 schistosomiasis 10.1
276 glomerulonephritis 10.1
277 spindle cell carcinoma 10.1
278 malignant ovarian brenner tumor 10.1
279 stomatitis 10.1
280 48,xyyy 10.1
281 granulocytopenia 10.1
282 endocrine gland cancer 10.1 TP53 PTEN HRAS ERBB2 EGFR CDKN2A
283 sweat gland cancer 10.1 TP53 KRT7 KRT20 KRT18 ERBB2
284 glioblastoma 10.1 TP53 PTEN HRAS ERBB3 ERBB2 EGFR
285 paronychia 10.1 HRAS EGFR
286 lymphoma 10.1
287 lynch syndrome 10.1
288 amyloidosis 10.1
289 meningitis 10.1
290 ovarian epithelial cancer 10.1
291 posttransplant acute limbic encephalitis 10.1
292 barrett esophagus 10.0 TP53 PTGS2 KRT7 KRT20 ERBB2 CDKN2A
293 gastrointestinal system disease 10.0 TP53 PTGS2 HRAS ERBB2 EGFR CDKN2A
294 intussusception 10.0
295 suppressor of tumorigenicity 3 10.0
296 osteogenic sarcoma 10.0
297 respiratory failure 10.0
298 xanthogranulomatous pyelonephritis 10.0
299 nephrotic syndrome 10.0
300 diarrhea 10.0
301 hyperparathyroidism 10.0
302 giant cell tumor 10.0
303 cystic kidney disease 10.0
304 severe combined immunodeficiency 10.0
305 peritonitis 10.0
306 priapism 10.0
307 pulmonary embolism 10.0
308 tetraploidy 10.0
309 urachal cyst 10.0
310 paraneoplastic syndromes 10.0
311 reproductive system disease 10.0 TP53 PTGS2 PTEN ERBB2 EGFR CDKN2A
312 adamantinoma of long bones 10.0 TP53 PTGS2 PTEN ERBB2 EGFR CDKN2A
313 aortic aneurysm, familial abdominal, 1 10.0
314 acanthosis nigricans 10.0
315 danubian endemic familial nephropathy 10.0
316 congenital anomalies of kidney and urinary tract 2 10.0
317 neutrophilia, hereditary 10.0
318 ureter, cancer of 10.0
319 ureterocele 10.0
320 chondrosarcoma 10.0
321 wilms tumor 5 10.0
322 polycystic kidney disease 10.0
323 interstitial nephritis 10.0
324 disseminated intravascular coagulation 10.0
325 neurogenic bladder 10.0
326 leiomyoma 10.0
327 bladder leiomyoma 10.0
328 interstitial cystitis 10.0
329 malignant fibroxanthoma 10.0
330 melanoma 10.0
331 aortic aneurysm 10.0
332 histiocytoma 10.0
333 fibrous histiocytoma 10.0
334 peripheral nervous system disease 10.0
335 cloacogenic carcinoma 10.0
336 neuropathy 10.0
337 autosomal dominant polycystic kidney disease 10.0
338 urethral diverticulum 10.0
339 renal tuberculosis 10.0
340 miliary tuberculosis 10.0
341 hypereosinophilic syndrome 10.0
342 cytokine deficiency 10.0
343 undifferentiated pleomorphic sarcoma 10.0
344 back pain 10.0
345 dysphagia 10.0
346 thyroid carcinoma 10.0
347 muir-torre syndrome 9.9
348 nevus, epidermal 9.9
349 nephrolithiasis, calcium oxalate 9.9
350 xeroderma pigmentosum, complementation group c 9.9
351 xeroderma pigmentosum, variant type 9.9
352 ataxia and polyneuropathy, adult-onset 9.9
353 yemenite deaf-blind hypopigmentation syndrome 9.9
354 microvascular complications of diabetes 3 9.9
355 microvascular complications of diabetes 4 9.9
356 microvascular complications of diabetes 6 9.9
357 microvascular complications of diabetes 7 9.9
358 membranous nephropathy 9.9
359 angina pectoris 9.9
360 lambert-eaton myasthenic syndrome 9.9
361 villous adenoma 9.9
362 thrombosis 9.9
363 pertussis 9.9
364 gonadal dysgenesis 9.9
365 cholera 9.9
366 urinary system disease 9.9
367 rectum cancer 9.9
368 colon adenocarcinoma 9.9
369 sensory peripheral neuropathy 9.9
370 kidney cancer 9.9
371 endometriosis 9.9
372 testicular cancer 9.9
373 acute kidney failure 9.9
374 proctitis 9.9
375 turner syndrome 9.9
376 skin disease 9.9
377 spindle cell sarcoma 9.9
378 seminoma 9.9
379 collecting duct carcinoma 9.9
380 clear cell adenocarcinoma 9.9
381 uremia 9.9
382 lymphopenia 9.9
383 superficial urinary bladder cancer 9.9
384 chronic kidney disease 9.9
385 herpes zoster 9.9
386 herpes simplex 9.9
387 exophthalmos 9.9
388 brenner tumor of ovary 9.9
389 malakoplakia 9.9
390 urachal cancer 9.9
391 spinal cord injury 9.9
392 malignant epithelial tumor of ovary 9.9
393 acute liver failure 9.9
394 hinman syndrome 9.9
395 polyploidy 9.9
396 overgrowth syndrome 9.9
397 pheochromocytoma 9.9
398 sarcoidosis 1 9.9
399 renal cell carcinoma, xp11-associated 9.9
400 mutagen sensitivity 9.9
401 central centrifugal cicatricial alopecia 9.9
402 adrenal gland pheochromocytoma 9.9
403 pulmonary sarcoidosis 9.9
404 keratosis 9.9
405 rectum adenocarcinoma 9.9
406 combined t cell and b cell immunodeficiency 9.9
407 myocarditis 9.9
408 pituitary adenoma 9.9
409 pituitary tumors 9.9
410 esophageal cancer 9.8 TP53 PTGS2 PTEN HRAS ERBB2 EGFR
411 uterine carcinosarcoma 9.8 TP53 PTGS2 PTEN HRAS ERBB3 ERBB2
412 leydig cell tumor 9.8
413 sertoli-leydig cell tumor 9.8
414 juvenile type testicular granulosa cell tumor 9.8
415 gastric cancer 9.7 TP53 PTGS2 PTEN KRT20 ERBB2 EGFR
416 atrial standstill 1 9.7
417 hypercarotenemia and vitamin a deficiency, autosomal dominant 9.7
418 hypercalcemia, infantile, 1 9.7
419 endosteal hyperostosis, autosomal dominant 9.7
420 hypochondroplasia 9.7
421 inclusion body myositis 9.7
422 kaposi sarcoma 9.7
423 lacrimal duct defect 9.7
424 systemic lupus erythematosus 9.7
425 mesothelioma, malignant 9.7
426 myositis 9.7
427 neurofibromatosis, type iv, of riccardi 9.7
428 alkaline phosphatase, plasma level of, quantitative trait locus 1 9.7
429 dowling-degos disease 1 9.7
430 retinal detachment 9.7
431 thrombophilia due to thrombin defect 9.7
432 thyroid cancer, nonmedullary, 1 9.7
433 triiodothyronine receptor auxiliary protein 9.7
434 tuberous sclerosis 1 9.7
435 renal hypodysplasia/aplasia 1 9.7
436 vitiligo-associated multiple autoimmune disease susceptibility 6 9.7
437 adrenocortical carcinoma, hereditary 9.7
438 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.7
439 enterocolitis 9.7
440 factor x deficiency 9.7
441 hemangiopericytoma, malignant 9.7
442 macular degeneration, age-related, 1 9.7
443 light fixation seizure syndrome 9.7
444 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
445 myocardial infarction 9.7
446 hepatitis c virus 9.7
447 thrombocytopenia 4 9.7
448 ewing sarcoma 9.7
449 myxoid liposarcoma 9.7
450 aspergillosis 9.7
451 immunodeficiency, common variable, 10 9.7
452 carbonic anhydrase va deficiency, hyperammonemia due to 9.7
453 hydrops, lactic acidosis, and sideroblastic anemia 9.7
454 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.7
455 adrenal cortical carcinoma 9.7
456 angiosarcoma 9.7
457 hyperphosphatemia 9.7
458 metabolic acidosis 9.7
459 hemorrhagic cystitis 9.7
460 infective endocarditis 9.7
461 cd40 ligand deficiency 9.7
462 colitis 9.7
463 scoliosis 9.7
464 bone resorption disease 9.7
465 myxofibrosarcoma 9.7
466 osteomyelitis 9.7
467 endocarditis 9.7
468 viral pneumonia 9.7
469 dirofilariasis 9.7
470 kuhnt-junius degeneration 9.7
471 hypospadias 9.7
472 sarcoma 9.7
473 keratomalacia 9.7
474 arteriovenous malformation 9.7
475 adult respiratory distress syndrome 9.7
476 pulmonary edema 9.7
477 hemopericardium 9.7
478 cardiac tamponade 9.7
479 infant gynecomastia 9.7
480 polycystic ovary syndrome 9.7
481 nephrosclerosis 9.7
482 pericardial effusion 9.7
483 allergic hypersensitivity disease 9.7
484 male infertility 9.7
485 pancytopenia 9.7
486 hepatitis a 9.7
487 gynecomastia 9.7
488 ehlers-danlos syndrome 9.7
489 urethritis 9.7
490 tuberous sclerosis 9.7
491 eclampsia 9.7
492 patent foramen ovale 9.7
493 urinary schistosomiasis 9.7
494 toxic shock syndrome 9.7
495 bacteriuria 9.7
496 prostatitis 9.7
497 candidiasis 9.7
498 hypersensitivity reaction type iii disease 9.7
499 ichthyosis 9.7
500 duodenal ulcer 9.7
501 cheilitis 9.7
502 neuroendocrine carcinoma 9.7
503 urethral stricture 9.7
504 giant cell reparative granuloma 9.7
505 viral hepatitis 9.7
506 thrombocytosis 9.7
507 granulomatous hepatitis 9.7
508 basal cell carcinoma 9.7
509 hematologic cancer 9.7
510 hemangioma 9.7
511 benign mesothelioma 9.7
512 renal adenoma 9.7
513 hemangioma of liver 9.7
514 phimosis 9.7
515 idiopathic interstitial pneumonia 9.7
516 acute pancreatitis 9.7
517 membranoproliferative glomerulonephritis 9.7
518 anuria 9.7
519 papillary cystadenocarcinoma 9.7
520 keratoacanthoma 9.7
521 embryonal rhabdomyosarcoma 9.7
522 rhabdomyosarcoma 9.7
523 teratoma 9.7
524 angiomyolipoma 9.7
525 liposarcoma 9.7
526 duodenal obstruction 9.7
527 ovarian cystadenocarcinoma 9.7
528 fallopian tube adenocarcinoma 9.7
529 extramedullary plasmacytoma 9.7
530 plasmacytoma 9.7
531 vaginal discharge 9.7
532 pulmonary fibrosis 9.7
533 thrombophlebitis 9.7
534 adrenal carcinoma 9.7
535 adrenal cortical adenocarcinoma 9.7
536 pancreatic adenocarcinoma 9.7
537 liver disease 9.7
538 syphilis 9.7
539 hyperglycemia 9.7
540 myopathy 9.7
541 bone giant cell tumor 9.7
542 large cell carcinoma 9.7
543 prostate adenoid cystic carcinoma 9.7
544 trachea carcinoma 9.7
545 infertility 9.7
546 myxoid leiomyosarcoma 9.7
547 lung oat cell carcinoma 9.7
548 eccrine acrospiroma 9.7
549 clear cell hidradenoma 9.7
550 acute pyelonephritis 9.7
551 sebaceous gland neoplasm 9.7
552 silent myocardial infarction 9.7
553 follicular adenoma 9.7
554 bladder urothelial papillary carcinoma 9.7
555 b-cell lymphoma 9.7
556 urethral benign neoplasm 9.7
557 urethra cancer 9.7
558 malignant pleural mesothelioma 9.7
559 diverticulitis 9.7
560 peptic ulcer disease 9.7
561 appendicitis 9.7
562 intestinal obstruction 9.7
563 ileus 9.7
564 actinomycosis 9.7
565 bullous pemphigoid 9.7
566 acute cor pulmonale 9.7
567 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.7
568 vasculitis 9.7
569 crohn's disease 9.7
570 lupus erythematosus 9.7
571 diabetes insipidus 9.7
572 allergic asthma 9.7
573 fasciitis 9.7
574 biliary tract disease 9.7
575 hydrocele 9.7
576 sickle cell disease 9.7
577 acrospiroma 9.7
578 cerebellar degeneration 9.7
579 chromophil renal cell carcinoma 9.7
580 enterovesical fistula 9.7
581 eosinophilic cystitis 9.7
582 heavy metal poisoning 9.7
583 human t-cell leukemia virus type 1 9.7
584 hypoadrenalism 9.7
585 ichthyosis, acquired 9.7
586 lymphangiectasis 9.7
587 lymphatic malformations 9.7
588 lymphomatoid papulosis 9.7
589 medullary sponge kidney 9.7
590 paraneoplastic cerebellar degeneration 9.7
591 piriformis syndrome 9.7
592 polymyositis 9.7
593 posterior urethral valves 9.7
594 prurigo nodularis 9.7
595 retroperitoneal fibrosis 9.7
596 skeletal dysplasias 9.7
597 stevens-johnson syndrome/toxic epidermal necrolysis 9.7
598 subacute cerebellar degeneration 9.7
599 testicular seminoma 9.7
600 aneurysm 9.7
601 encephalopathy 9.7
602 myoclonus 9.7
603 syncope 9.7
604 multicystic dysplastic kidney 9.7
605 glial tumor 9.7
606 virus-associated trichodysplasia spinulosa 9.7
607 primary localized amyloidosis 9.7
608 eosinophilic colitis 9.7
609 mucinous adenocarcinoma of the appendix 9.7
610 argyria 9.7
611 rare surgical neurologic disease 9.7
612 congenital anomaly of the inferior vena cava 9.7
613 pituitary adenoma, prolactin-secreting 9.7
614 anogenital venereal wart 9.7
615 acromegaly 9.7
616 ureter inverted papilloma 9.7
617 ataxia-telangiectasia 9.6
618 acute promyelocytic leukemia 9.6
619 telangiectasis 9.6
620 impotence 9.6
621 hypoxia 9.6
622 gastrointestinal system cancer 9.6 TP53 PTGS2 PTEN KRT7 HRAS ERBB2
623 squamous cell carcinoma, head and neck 9.5 TP53 PTGS2 PTEN HRAS FGFR3 ERBB3
624 lung cancer susceptibility 3 9.2 TP53 PTGS2 KRT7 KRT20 HRAS FGFR3
625 large intestine cancer 9.2 TP53 PTGS2 PTEN KRT7 KRT20 HRAS

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to Transitional Cell Carcinoma

Symptoms & Phenotypes for Transitional Cell Carcinoma

GenomeRNAi Phenotypes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

26 (showing 9, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.96 EGFR HRAS
2 Decreased viability GR00221-A-1 9.96 CDH1 CDKN2A EGFR FGFR3 HRAS
3 Decreased viability GR00221-A-2 9.96 FGFR3 HRAS
4 Decreased viability GR00221-A-3 9.96 CDKN2A FGFR3 HRAS
5 Decreased viability GR00221-A-4 9.96 CDKN2A EGFR
6 Decreased viability GR00301-A 9.96 CDH1
7 Decreased viability GR00402-S-2 9.96 CDH1 CDKN2A EGFR FGFR3 HRAS
8 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 EGFR ERBB2 FGFR3 HRAS PTEN
9 Reduced mammosphere formation GR00396-S 9.28 BRINP1 CDH1 EGFR ERBB3 HRAS KRT18

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

46 (showing 15, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
2 growth/size/body region MP:0005378 10.34 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
3 cellular MP:0005384 10.29 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
4 mortality/aging MP:0010768 10.28 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
5 digestive/alimentary MP:0005381 10.24 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
6 embryo MP:0005380 10.22 CDH1 CDKN2A EGFR ERBB2 ERBB3 KRT18
7 endocrine/exocrine gland MP:0005379 10.16 CDH1 CDKN2A EGFR ERBB2 ERBB3 HRAS
8 integument MP:0010771 10.16 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
9 neoplasm MP:0002006 10.1 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
10 normal MP:0002873 10.02 CDH1 EGFR ERBB2 ERBB3 FGFR3 HRAS
11 no phenotypic analysis MP:0003012 9.97 BRINP1 CDH1 CDKN2A EGFR FGFR3 HRAS
12 renal/urinary system MP:0005367 9.81 EGFR FGFR3 HRAS KRT7 PTEN PTGS2
13 pigmentation MP:0001186 9.65 CDKN2A EGFR ERBB3 PTEN TP53
14 respiratory system MP:0005388 9.61 CDKN2A EGFR ERBB2 ERBB3 FGFR3 HRAS
15 skeleton MP:0005390 9.28 BRINP1 CDKN2A EGFR ERBB2 FGFR3 HRAS

Drugs & Therapeutics for Transitional Cell Carcinoma

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 329, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lapatinib Approved, Investigational Phase 2, Phase 3 388082-78-8, 231277-92-2 208908 9941095
2
Panitumumab Approved, Investigational Phase 3 339177-26-3 50070211
3
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
4
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
5
Aminolevulinic acid Approved Phase 3 106-60-5 137
6
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
7
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
8
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
9
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
10
Ethanol Approved Phase 3 64-17-5 702
11
Methylcobalamin Approved, Experimental, Investigational Phase 3 13422-55-4
12
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
13
Durvalumab Approved, Investigational Phase 3 1428935-60-7
14
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
15
Lenvatinib Approved, Investigational Phase 3 417716-92-8
16
Tranexamic Acid Approved Phase 2, Phase 3 1197-18-8 5526
17
Ramucirumab Approved, Investigational Phase 3 947687-13-0
18
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
19
Gemcitabine Approved Phase 3 95058-81-4 60750
20
leucovorin Approved Phase 3 58-05-9 143 6006
21
Vinblastine Approved Phase 3 865-21-4 241903 13342
22
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
23
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
24
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
25
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
26
Sargramostim Approved, Investigational Phase 2, Phase 3 83869-56-1, 123774-72-1
27
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
28
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
29
Valrubicin Approved Phase 2, Phase 3 56124-62-0 41744
30
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
31
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
32
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
33
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
35 Tocotrienol Investigational Phase 3 6829-55-6
36
Levulinic acid Experimental Phase 3 123-76-2 11579
37
Fenretinide Investigational Phase 3 65646-68-6
38
Cobalamin Experimental Phase 3 13408-78-1 6857388
39
Tremelimumab Investigational Phase 3 745013-59-6
40 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
41
Cediranib Investigational Phase 3 288383-20-0 9933475
42 Tocopherols Phase 3
43 Tocotrienols Phase 3
44 Liposomal amphotericin B Phase 2, Phase 3
45 Antiparasitic Agents Phase 3
46 Antiprotozoal Agents Phase 3
47 Antioxidants Phase 3
48 Protective Agents Phase 3
49 Photosensitizing Agents Phase 3
50 Vitamin B3 Phase 3
51 Nicotinic Acids Phase 3
52 Hypolipidemic Agents Phase 3
53 Lipid Regulating Agents Phase 3
54 Vasodilator Agents Phase 3
55 Pharmaceutical Solutions Phase 3
56 Antibodies Phase 3
57 Antibodies, Monoclonal Phase 3
58 Immunoglobulins Phase 3
59 Micronutrients Phase 3
60 Trace Elements Phase 3
61 Vitamins Phase 3
62 Hematinics Phase 3
63 Vitamin B 12 Phase 3
64 Nutrients Phase 3
65 Vitamin B12 Phase 3
66 Carotenoids Phase 3
67 Hemostatics Phase 2, Phase 3
68 Fibrinolytic Agents Phase 2, Phase 3
69 Coagulants Phase 2, Phase 3
70 Antifibrinolytic Agents Phase 2, Phase 3
71 taxane Phase 3
72 Immunoglobulin G Phase 3
73 Adjuvants, Immunologic Phase 3
74 Immunologic Factors Phase 3
75 Tubulin Modulators Phase 3
76 Antimitotic Agents Phase 3
77 Immunosuppressive Agents Phase 3
78 Anti-Infective Agents Phase 3
79 Antimetabolites Phase 3
80 Antiviral Agents Phase 3
81 Antimetabolites, Antineoplastic Phase 3
82 Anti-Bacterial Agents Phase 3
83 Antibiotics, Antitubercular Phase 3
84 Topoisomerase Inhibitors Phase 3
85 Alkylating Agents Phase 2, Phase 3
86 Nucleic Acid Synthesis Inhibitors Phase 3
87 Mitomycins Phase 2, Phase 3
88 Folic Acid Antagonists Phase 3
89 Vitamin B9 Phase 3
90 Folate Phase 3
91 Vitamin B Complex Phase 3
92 Antineoplastic Agents, Phytogenic Phase 3
93 interferons Phase 2, Phase 3
94 Protein Kinase Inhibitors Phase 3
95 Fluoroquinolones Phase 3
96 Cytochrome P-450 Enzyme Inhibitors Phase 3
97 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
98
Liposomal doxorubicin Phase 3 31703
99 Dermatologic Agents Phase 3
100
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
101
tannic acid Approved Phase 2 1401-55-4
102
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
103
Nintedanib Approved Phase 2 656247-17-5 56843413
104
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
105
Belinostat Approved, Investigational Phase 1, Phase 2 866323-14-0
106
Hyaluronic acid Approved, Vet_approved Phase 2 9004-61-9 53477741
107
Ifosfamide Approved Phase 2 3778-73-2 3690
108
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
109
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
110
afatinib Approved Phase 2 439081-18-2, 850140-72-6 10184653
111
Altretamine Approved Phase 2 645-05-6 2123
112
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
113
Tamoxifen Approved Phase 2 10540-29-1 2733526
114
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
115
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751